JP2022538505A - ミクロ分子ｐｉ４ｋｉｉｉａ阻害剤組成物、その調製方法およびその使用 - Google Patents

ミクロ分子ｐｉ４ｋｉｉｉａ阻害剤組成物、その調製方法およびその使用 Download PDF

Info

Publication number
JP2022538505A
JP2022538505A JP2022526849A JP2022526849A JP2022538505A JP 2022538505 A JP2022538505 A JP 2022538505A JP 2022526849 A JP2022526849 A JP 2022526849A JP 2022526849 A JP2022526849 A JP 2022526849A JP 2022538505 A JP2022538505 A JP 2022538505A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oil
composition according
pao
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022526849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538505A5 (https=
Inventor
フアン，フーデ
ワン，フェン
ヤン，シュウ
ジャオ，チャンピン
チョウ，シャオジュン
Original Assignee
ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド filed Critical ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド
Publication of JP2022538505A publication Critical patent/JP2022538505A/ja
Publication of JP2022538505A5 publication Critical patent/JP2022538505A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2022526849A 2019-07-05 2020-07-06 ミクロ分子ｐｉ４ｋｉｉｉａ阻害剤組成物、その調製方法およびその使用 Pending JP2022538505A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/094831 2019-07-05
CN2019094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
JP2022538505A true JP2022538505A (ja) 2022-09-02
JP2022538505A5 JP2022538505A5 (https=) 2023-07-12

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022526849A Pending JP2022538505A (ja) 2019-07-05 2020-07-06 ミクロ分子ｐｉ４ｋｉｉｉａ阻害剤組成物、その調製方法およびその使用

Country Status (15)

Country Link
US (1) US20230115711A1 (https=)
EP (1) EP3995134A4 (https=)
JP (1) JP2022538505A (https=)
KR (1) KR20220071175A (https=)
CN (2) CN118105372A (https=)
AU (1) AU2020309681A1 (https=)
BR (1) BR112022000155A2 (https=)
CA (1) CA3149104A1 (https=)
CO (1) CO2022001218A2 (https=)
IL (1) IL289586A (https=)
MX (1) MX2022000287A (https=)
PE (1) PE20220942A1 (https=)
PH (1) PH12022550254A1 (https=)
TW (1) TW202126294A (https=)
WO (1) WO2021004422A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
JP2024537837A (ja) * 2021-09-30 2024-10-16 ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド ハロゲン化フェニルアルシンオキシド化合物およびその用途
CN116478954B (zh) * 2023-02-14 2025-06-10 中国农业大学 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688206A (zh) * 2007-07-05 2010-03-31 诺瓦提斯公司 用于靶向病毒感染的dsRNA
JP2018521112A (ja) * 2015-04-30 2018-08-02 ジャンスー・ヌオ−ベータ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド アルツハイマー病の治療におけるＰＩ４ＫＩＩＩαタンパク質および関連膜タンパク質複合体の利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365110A1 (en) * 2001-07-10 2003-07-15 Massachusetts Institute Of Technology Small molecule microarrays
CN112437674A (zh) * 2018-04-11 2021-03-02 新墨西哥科技大学研究园公司 用于药物递送的脂质前药
BR112022019864A2 (pt) * 2020-03-31 2022-11-16 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Composto de oxofenilarsina deuterada e uso do mesmo
JP2024537837A (ja) * 2021-09-30 2024-10-16 ヌオ－ベータ・ファーマシューティカル・テクノロジー（シャンハイ）カンパニー・リミテッド ハロゲン化フェニルアルシンオキシド化合物およびその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101688206A (zh) * 2007-07-05 2010-03-31 诺瓦提斯公司 用于靶向病毒感染的dsRNA
JP2018521112A (ja) * 2015-04-30 2018-08-02 ジャンスー・ヌオ−ベータ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド アルツハイマー病の治療におけるＰＩ４ＫＩＩＩαタンパク質および関連膜タンパク質複合体の利用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROGRESS IN BIOCHEM BIOPHYS, vol. 40(10), JPN6024026160, 2013, pages 1008 - 13, ISSN: 0005494239 *

Also Published As

Publication number Publication date
AU2020309681A1 (en) 2022-02-24
KR20220071175A (ko) 2022-05-31
CO2022001218A2 (es) 2022-05-20
IL289586A (en) 2022-03-01
WO2021004422A1 (zh) 2021-01-14
CA3149104A1 (en) 2021-01-14
EP3995134A4 (en) 2023-07-12
MX2022000287A (es) 2022-06-16
US20230115711A1 (en) 2023-04-13
EP3995134A1 (en) 2022-05-11
CN118105372A (zh) 2024-05-31
CN114555056B (zh) 2024-01-05
TW202126294A (zh) 2021-07-16
PE20220942A1 (es) 2022-05-31
PH12022550254A1 (en) 2023-06-26
CN114555056A (zh) 2022-05-27
BR112022000155A2 (pt) 2022-04-12

Similar Documents

Publication Publication Date Title
CA2866067C (en) Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
KR101651448B1 (ko) 체지방을 국소적으로 증가시키는 방법 및 조성물
JP2014513094A (ja) 親油性医薬用薬剤の改良された非経口製剤ならびにそれを調製および使用するための方法
KR20170008311A (ko) 안정한 카나비노이드 제형
JP2022538505A (ja) ミクロ分子ｐｉ４ｋｉｉｉａ阻害剤組成物、その調製方法およびその使用
JP2004509854A (ja) バルプロ酸のリン脂質誘導体およびそれらの混合物
DK2528598T3 (en) RELATIONS TO suppress PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT
JP2007510737A (ja) 癌処置のためのセラミド異化阻害剤としてのｐｐｍｐ
HK40074190B (zh) 小分子PI4KIIIα抑制剂组合物、其制备方法及用途
HK40073830A (en) Micromolecule pi4kiiialpha inhibitor composition, preparation method therefor and use thereof
HK40074190A (en) MICROMOLECULE PI4KIIIα INHIBITOR COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF
EP3984989A1 (en) Ibuprofen ester prodrug, pharmaceutical composition and preparation method and use
OA20568A (en) Micromolecule PI4Klllα inhibitor composition, preparation method therefor and use thereof.
CN115531306B (zh) 一种注射用左奥硝唑衍生物乳状制剂及其制备方法
EP1648413B1 (en) Pharmaceutical compositions of short-acting sedative hypnotic agent
SK284247B6 (sk) Lipozómový prípravok 6,9- bis[(2-aminoetyl)amino]benzo[g]izochinolín-5,10-dión dimaleátu a jeho použitie
WO2016033549A2 (en) (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JP7257091B2 (ja) 認知症の治療及び予防薬
CA2880399C (en) Use of bimatoprost free acid administered to the skin to reduce adipose tissue
CN103260614B (zh) 联合疗法
KR20180030025A (ko) 질환의 치료를 위한 헤테로아릴 카보나이트릴
JPH08157391A (ja) ナフトエ酸誘導体の吸収促進組成物
CN120004750A (zh) 一种无菌的双他喷他多癸二酸酯及其制备方法与用途
HK1177423B (en) Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
HK1090841B (en) Pharmaceutical compositions of short-acting sedative hypnotic agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241226